{"schema_version":"1","generated_at":"2026-11-07T11:13:50.840Z","data_as_of":null,"url":"https://www.findmykol.com/kol/joseph-pearlberg","json_url":"https://www.findmykol.com/kol/joseph-pearlberg/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"joseph-pearlberg","name":"Joseph Pearlberg","credential":"MD, PhD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Deerfield","institution_url":"https://www.findmykol.com/institution/deerfield","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1164536066","openalex":"A5033846219"},"summary":"Joseph Pearlberg is an Oncology physician affiliated with Deerfield. OpenAlex indexes 38 publications with 3,472 citations (h-index 21).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":38,"cited_by_count":3472,"h_index":21,"latest_activity_year":2020,"source":"works"},"publications":{"total":38,"shown":5,"withheld":33,"matched_by":"OpenAlex author record","recent":[{"title":"Let's get americans back to work again","year":2020,"journal":"Contemporary Clinical Trials Communications","source_url":"https://doi.org/10.1016/j.conctc.2020.100559","status":"verified"},{"title":"Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors","year":2017,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.am2017-ct089","status":"verified"},{"title":"Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer","year":2016,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2016.67.1891","status":"verified"},{"title":"Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors","year":2016,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1078-0432.ccr-16-1764","status":"verified"},{"title":"Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-δ,γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab","year":2016,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.v128.22.2979.2979","status":"verified"}],"source":"works"},"contact":{"address_1":"240 LONGWOOD AVE","address_2":"HARVARD MEDICAL SCHOOL, LHRRB ROOM 212","city":"Boston","state":"MA","zip":"021155701","phone":"617-943-0067","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1164536066","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":33}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2009-10-26","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"}},"methodology_url":"https://www.findmykol.com/about#methodology"}